{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6"},{"groupId":"OG001","value":"54.8"}]}],"title":"Cycle 1 Day 1 - Baseline (n=188, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1"},{"groupId":"OG001","value":"95.0"}]}],"title":"Cycle 2 Day 0 (n=183, 180)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"99.4"}]}],"title":"Cycle 3 Day 1 (n=175, 175)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 4 Day 1 (n=178, 180)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 5 Day 1 (n=179, 176)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 6 Day 1 (n=173, 175)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 7 Day 1 (n=178, 173)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}],"title":"Cycle 8 Day 1 (n=175, 174)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Depletion is defined as a cluster of differentiation (CD) 19 value \\<80 cells per cubic millimeter (cells/mm\\^3).","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"NUMBER","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2","title":"Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}